Atea Pharmaceuticals PE ratio AVIR

Share price divided by earnings per share over the last twelve months, since 2021.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 10.5×; Feb 2023
Peer median: 11.5×

Atea Pharmaceuticals has no meaningful PE ratio today: it lost $2.08 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Feb 2023, at 10.5×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	10.5×	10.5×	14.1×
2022	13.7×	4.1×	76.5×
2021	22.9×	20.4×	29.1×

Against its peers

Companies in Drug Manufacturers - General nearest Atea Pharmaceuticals' size, closest first, today.

Company	PE ratio
AVIRAtea Pharmaceuticals	n/m
ARVNArvinas	45.6×
NATRNatures Sunshine Products	12.0×
PBYIPuma Biotechnology	21.2×
IRWDIronwood Pharmaceuticals	4.5×
ZVRAZevra Therapeutics	10.5×
CRMDCorMedix	3.7×
COLLCollegium Pharmaceutical	18.5×
ABUSArbutus Biopharma	5.4×
AMPHAmphastar Pharmaceuticals	14.8×
OMEROmeros	10.9×
Peer median	11.5×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Atea Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.